Departmental Papers (Dental)
Document Type
Journal Article
Date of this Version
12-2009
Publication Source
Trends in Plant Science
Volume
14
Issue
12
Start Page
669
Last Page
679
DOI
10.1016/j.tplants.2009.09.009
Abstract
Plant cells are ideal bioreactors for the production and oral delivery of vaccines and biopharmaceuticals, eliminating the need for expensive fermentation, purification, cold storage, transportation and sterile delivery. Plant-made vaccines have been developed for two decades but none has advanced beyond Phase I. However, two plant-made biopharmaceuticals are now advancing through Phase II and Phase III human clinical trials. In this review, we evaluate the advantages and disadvantages of different plant expression systems (stable nuclear and chloroplast or transient viral) and their current limitations or challenges. We provide suggestions for advancing this valuable concept for clinical applications and conclude that greater research emphasis is needed on large scale production, purification, functional characterization, oral delivery and preclinical evaluation.
Copyright/Permission Statement
© <2009>. This manuscript version is made available under the CC-BY-NC-ND 4.0 license http://creativecommons.org/licenses/by-nc-nd/4.0/
Recommended Citation
Daniell, H., Singh, N. D., Mason, H., & Streatfield, S. J. (2009). Plant-Made Vaccine Antigens and Biopharmaceuticals. Trends in Plant Science, 14 (12), 669-679. http://dx.doi.org/10.1016/j.tplants.2009.09.009
Date Posted: 01 March 2022
This document has been peer reviewed.
Comments
At the time of publication, author Henry Daniell was affiliated with the University of Central Florida. Currently, he is a faculty member at the School of Dental Medicine at the University of Pennsylvania.